References


  1. Abdo CH, Valadares AL, Oliveira WM Jr, Scanavino MT, Afif-Abdo J. Hypoactive sexual desire disorder in a population-based study of Brazilian women: associated factors classified according to their importance. Menopause. 2010;17(6):1114-1121.
  2. Abdolrasulnia M, Shewchuk RM, Roepke N, Granstaff US, Dean J, Foster JA, Goldstein AT, Casebeer L. Management of female sexual problems: perceived barriers, practice patterns, and confidence among primary care physicians and gynecologists. J Sex Med. 2010;7(7):2499-2508.
  3. Al-Azzawi F, Bitzer J, Brandenburg U, Castelo-Branco C, Graziottin A, Kenemans P, Lachowsky M, Mimoun S, Nappi RE, Palacios S, Schwenkhagen A, Studd J, Wylie K, Zahradnik HP. Therapeutic options for postmenopausal female sexual dysfunction. Climacteric. 2010;13(2):103-120. Review.
  4. Anderson JL. Acknowledging female sexual dysfunction in women with cancer. Clin J Oncol Nurs. 2013;17(3):233-235.
  5. Anis TH, Gheit SA, Saied HS, Al kherbash SA. Arabic translation of Female Sexual Function Index and validation in an Egyptian population. J Sex Med. 2011;8(12):3370-3378.
  6. Aubert Y, Bohl MA, Lange JR, Diol NR, Allers KA, Sommer B, Datson NA, Abbott DH. Chronic systemic administration of serotonergic ligands flibanserin and 8-OH-DPAT enhance HPA axis responses to restraint in female marmosets. Psychoneuroendocrinology. 2013;38(1):145-154.
  7. Aubert Y, Gustison ML, Gardner LA, Bohl MA, Lange JR, Allers KA, Sommer B,Datson NA, Abbott DH. Flibanserin and 8-OH-DPAT implicate serotonin in association between female marmoset monkey sexual behavior and changes in pair-bond quality. J Sex Med. 2012;9(3):694-707.
  8. Basson R, Berman J, Burnett A, et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol. 2000;163(3):888-893.
  9. Basson R, Brotto LA, Petkau AJ, Labrie F. Role of androgens in women's sexual dysfunction. Menopause. 2010;17(5):962-971.
  10. Berman L, Berman J, Felder S, et al. Seeking help for sexual function complaints: what gynecologists need to know about the female patient's experience. Fertil Steril. 2003;79(3):572-576.
  11. Bianchi-Demicheli F, Cojan Y, Waber L, Recordon N, Vuilleumier P, Ortigue S. Neural bases of hypoactive sexual desire disorder in women: an event-related FMRI study. J Sex Med. 2011;8(9):2546-2559.
  12. Bitzer J, Giraldi A, Pfaus J.Sexual desire and hypoactive sexual desire disorder in women. Introduction and overview. Standard operating procedure (SOP Part 1).J Sex Med. 2013;10(1):36-49.
  13. Bloemers J, Gerritsen J, Bults R, Koppeschaar H, Everaerd W, Olivier B, Tuiten A. Induction of sexual arousal in women under conditions of institutional and ambulatory laboratory circumstances: a comparative study. J Sex Med. 2010;7(3):1160-1176.
  14. Bloemers J, Scholte HS, van Rooij K, Goldstein I, Gerritsen J, Olivier B, Tuiten A. Reduced gray matter volume and increased white matter fractional anisotropy in women with hypoactive sexual desire disorder. J Sex Med. 2014;11(3):753-767.
  15. Bloemers J, van Rooij K, Poels S, Goldstein I, Everaerd W, Koppeschaar H, Chivers M, Gerritsen J, van Ham D, Olivier B, Tuiten A.Toward personalized sexual medicine (part 1): integrating the "dual control model" into differential drug treatments for Hypoactive Sexual Desire Disorder and female sexual arousal disorder. J Sex Med. 2013;10(3):791-809.
  16. Bradford A.Listening to placebo in clinical trials for female sexual dysfunction. J Sex Med. 2013;10(2):451-459.
  17. Brauer M, van Leeuwen M, Janssen E, Newhouse SK, Heiman JR, Laan E. Attentional and Affective Processing of Sexual Stimuli in Women with Hypoactive Sexual Desire Disorder. 2012;41(4):891-905.
  18. Brotto LA, Petkau AJ, Labrie F, Basson R. Predictors of sexual desire disorders in women. J Sex Med. 2011;8(3):742-753.
  19. Brotto LA. The DSM diagnostic criteria for hypoactive sexual desire disorder in women. Arch Sex Behav. 2010;39(2):221-239. Review.
  20. Burri A, Spector T, Rahman Q.  A Discordant Monozygotic Twin Approach to Testing Environmental Influences on Sexual Dysfunction in Women. Arch Sex Behav. 2013 Apr 20. [Epub ahead of print]
  21. Burri A, Spector T, Rahman Q.The etiological relationship between anxiety sensitivity, sexual distress, and female sexual dysfunction is partly genetically moderated. J Sex Med. 2012;9(7):1887-1896.
  22. Carvalheira AA, Brotto LA, Leal I. Women's motivations for sex: exploring the diagnostic and statistical manual, fourth edition, text revision criteria for hypoactive sexual desire and female sexual arousal disorders. J Sex Med. 2010;7(4 Pt 1):1454-1463.
  23. CAUSE Distinguished Faculty Web conference, conducted October 29, 2008. Participant post-activity evaluations and comments received from CIEF/CAUSE/TU initiative activities.
  24. Chen CH, Lin YC, Chiu LH, Chu YH, Ruan FF, Liu WM, Wang PH.Female sexual dysfunction: definition, classification, and debates. Taiwan J Obstet Gynecol. 2013;52(1):3-7.
  25. Clayton AH, Dennerstein L, Pyke R, Sand M. Flibanserin: a potential treatment for Hypoactive Sexual Desire Disorder in premenopausal women. Womens Health (Lond Engl). 2010;6(5):639-653. Review.
  26. Clayton AH, DeRogatis LR, Rosen RC, Pyke R.Intended or unintended consequences? The likely implications of raising the bar for sexual dysfunction diagnosis in the proposed DSM-V revisions: 2. For women with loss of subjective sexual arousal.J Sex Med. 2012;9(8):2040-2006.
  27. Clayton AH, Goldfischer E, Goldstein I, DeRogatis L, Nappi R, Lewis-D'Agostino DJ, Kimura T, Hebert A, Pyke R. Validity of the decreased sexual desire screener for diagnosing hypoactive sexual desire disorder. J Sex Marital Ther. 2013;39(2):132-143.
  28. Clayton AH, Goldfischer ER, Goldstein I, Derogatis L, Lewis-D'Angostino DJ, Pyke R. Validation of the decreased sexual desire screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD). J Sex Med. 2009;6(3):730-738.
  29. Clayton AH, Goldmeier D, Nappi RE, Wunderlich G, Lewis-D'Agostino DJ, Pyke R. Validation of the sexual interest and desire inventory-female in hypoactive sexual desire disorder. J Sex Med. 2010;7(12):3918-3928.
  30. Clayton AH, Groth J.Etiology of female sexual dysfunction. Womens Health (Lond Engl). 2013;9(2):135-137.
  31. Clayton AH, Segraves RT, Bakish D, Goldmeier D, Tignol J, van Lunsen RH, Nappi RE, Wunderlich G, Kimura T, Lewis-D'Agostino DJ, Pyke R. Cutoff score of the sexual interest and desire inventory-female for diagnosis of hypoactive sexual desire disorder. J Womens Health (Larchmt). 2010;19(12):2191-2195.
  32. Clayton AH. The pathophysiology of hypoactive sexual desire disorder in women. Int J Gynaecol Obstet. 2010;110(1):7-11. Review.
  33. Clegg M, Towner A, Wylie K.Should questionnaires of female sexual dysfunction be used in routine clinical practice? Maturitas. 2012;72(2):160-164.
  34. Connor MK, Maserejian NN, De Rogatis L, Meston CM, Gerstenberger EP, Rosen RC. Sexual desire, distress, and associated factors in premenopausal women: preliminary findings from the hypoactive sexual desire disorder registry for women. J Sex Marital Ther. 2011;37(3):176-189.
  35. Cortelazzi D, Marconi A, Guazzi M, Cristina M, Zecchini B, Veronelli A, Cattalini C, Innocenti A, Bosco G, Pontiroli AE. Sexual dysfunction in pre-menopausal diabetic women: clinical, metabolic, psychological, cardiovascular, and neurophysiologic correlates. Acta Diabetol. 2013 May 16. [Epub ahead of print]
  36. Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med. 2008;359(19):2005-2017.
  37. Davis SR, Worsley R. Androgen treatment of postmenopausal women. J Steroid Biochem Mol Biol. 2013 May 29. [Epub ahead of print]
  38. Davis SR. Should women receive androgen replacement therapy, and if so, how?  Clin Endocrinol (Oxf). 2010;72(2):149-154.
  39. De Franciscis P, Mainini G, Messalli EM, Trotta C, Luisi A, Laudando E, Marino G, Della Puca G, Cerreto FV, Torella M. Arterial hypertension and female sexual dysfunction in postmenopausal women.Clin Exp Obstet Gynecol. 2013;40(1):58-60.
  40. Dennerstein L, Hayes R, Sand M, Lehert P. Attitudes toward and frequency of partner interactions among women reporting decreased sexual desire. J Sex Med. 2009;6(6):1668-1673.
  41. DeRogatis L, Pyke R, McCormack J, Hunter A, Harding G. Does the Female Sexual Distress Scale Revised cover the feelings of women with HSDD? J Sex Med. 2011;8(10):2810-2815.
  42. DeRogatis LR, Allgood A, Auerbach P, Eubank D, Greist J, Bharmal M, Zipfel L, Guo CY. Validation of a Women's Sexual Interest Diagnostic Interview--Short Form (WSID-SF) and a Daily Log of Sexual Activities (DLSA) in postmenopausal women with hypoactive sexual desire disorder. J Sex Med. 2010;7(2 Pt 2):917-927.
  43. Derogatis LR, Clayton AH, Goldstein A, Lewis-D'Agostino D, Wunderlich G, Cotton D. eDiary and Female Sexual Distress Scale(©) in evaluating distress in hypoactive sexual desire disorder (HSDD). J Sex Res. 2011;48(6):565-572.
  44. Derogatis LR, Komer L, Katz M, Moreau M, Kimura T, Garcia M Jr, Wunderlich G, Pyke R; VIOLET Trial Investigators. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study. J Sex Med. 2012;9(4):1074-1085.
  45. DeRogatis LR. Consultation corner. The latest on female sexual health. Johns Hopkins Med Lett Health After 50. 2010;22(9):6-7.
  46. Dhanuka I, Simon JA. Flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women. Expert Opin Pharmacother. 2015 Sep 22:1-7. [Epub ahead of print]
  47. Dhingra C, Kellogg-Spadt S, McKinney TB, Whitmore KE. Urogynecological causes of pain and the effect of pain on sexual function in women. Female Pelvic Med Reconstr Surg. 2012;18(5):259-267.
  48. Dimitropoulos K, Bargiota A, Mouzas O, Melekos M, Tzortzis V, Koukoulis G. Sexual functioning and distress among premenopausal women with uncomplicated type 1 diabetes. J Sex Med. 2012;9(5):1374-1381.
  49. Echeverry MC, Arango A, Castro B, Raigosa G. Study of the prevalence of female sexual dysfunction in sexually active women 18 to 40 years of age in Medellín, Colombia. J Sex Med. 2010;7(8):2663-2669.
  50. Elsamra S, Nazmy M, Shin D, Fisch H, Sawczuk I, Fromer D. Female sexual dysfunction in urological patients: findings from a major metropolitan area in the USA. BJU Int. 2010;106(4):524-526.
  51. Esposito K, Ciotola M, Marfella R, Di Tommaso D, Cobellis L, Giugliano D. The metabolic syndrome: a cause of sexual dysfunction in women. Int J Impot Res. 2005;17(3):224-226.
  52. Esposito K, Maiorino MI, Bellastella G, Giugliano F, Romano M, Giugliano D. Determinants of female sexual dysfunction in type 2 diabetes. Int J Impot Res. 2010;22(3):179-184.
  53. Fabre LF, Smith LC. The effect of major depression on sexual function in women. J Sex Med. 2012 Jan;9(1):231-239.
  54. Fakhri A, Pakpour AH, Burri A, Morshedi H, Zeidi IM. The Female Sexual Function Index: Translation and Validation of an Iranian Version. J Sex Med. 2012;9(2):514-23.
  55. Fanfulla F, Camera A, Fulgoni P, Chiovato L, Nappi RE. Sexual dysfunction in obese women: does obstructive sleep apnea play a role?Sleep Med. 2013;14(3):252-256.
  56. Farina B, Mazzotti E, Pasquini P, Mantione MG. Somatoform and psychoform dissociation among women with orgasmic and sexual pain disorders. J Trauma Dissociation. 2011;12(5):526-534.
  57. Farrell J, Cacchioni T.The medicalization of women's sexual pain.J Sex Res. 2012;49(4):328-336.
  58. Ferger B, Shimasaki M, Ceci A, Ittrich C, Allers KA, Sommer B. Flibanserin, a drug intended for treatment of hypoactive sexual desire disorder in pre-menopausal women, affects spontaneous motor activity and brain neurochemistry in female rats. Naunyn Schmiedebergs Arch Pharmacol. 2010;381(6):573-579.
  59. Flibanserin (Addyi) for hypoactive sexual desire disorder. Med Lett Drugs Ther. 2015;57(1478):133-135.
  60. Flibanserin [briefing document]. Ingelheim am Rhein, Germany: Boehringer Ingelheim; May 14, 2010. link. Accessed July 17, 2013.
  61. Foley K, Foley D, Johnson BH. Healthcare resource utilization and expenditures of women diagnosed with hypoactive sexual desire disorder. J Med Econ. 2010;13(4):583-590.
  62. Fooladi E, Davis SR. An update on the pharmacological management of female sexual dysfunction. Expert Opin Pharmacother. 2012;13(15):2131-42.
  63. Frank JE, Mistretta P, Will J. Diagnosis and treatment of female sexual dysfunction. Am Fam Physician. 2008;77(5):635-642. 
  64. Gellad WF, Flynn KE, Alexander GC. Evaluation of Flibanserin: Science and Advocacy at the FDA. JAMA. 2015;314(9):869-70.
  65. Gelez H, Greggain-Mohr J, Pfaus JG, Allers KA, Giuliano F. Flibanserin treatment increases appetitive sexual motivation in the female rat. J Sex Med. 2013;10(5):1231-9.
  66. Gerstenberger EP, Rosen RC, Brewer JV, Meston CM, Brotto LA, Wiegel M, Sand M. Sexual desire and the female sexual function index (FSFI): a sexual desire cutpoint for clinical interpretation of the FSFI in women with and without hypoactive sexual desire disorder. J Sex Med. 2010 Sep;7(9):3096-3103.
  67. Ghanbarzadeh N, Nadjafi-Semnani M, Ghanbarzadeh MR, Nadjfai-Semnani A, Nadjfai-Semnani F.Female sexual dysfunction in Iran: study of prevalence and risk factors. Arch Gynecol Obstet. 2013;287(3):533-539.
  68. Giraldi A, Rellini A, Pfaus JG, Bitzer J, Laan E, Jannini EA, Fugl-Meyer AR. Questionnaires for assessment of female sexual dysfunction: a review and proposal for a standardized screener. J Sex Med. 2011;8(10):2681-2706.
  69. Giugliano F, Maiorino MI, Di Palo C, Autorino R, De Sio M, Giugliano D, Esposito K. Adherence to Mediterranean diet and sexual function in women with type 2 diabetes. J Sex Med. 2010;7(5):1883-1890.
  70. Goldfischer ER, Breaux J, Katz M, Kaufman J, Smith WB, Kimura T, Sand M, Pyke R. Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial. J Sex Med. 2011;8(11):3160-3172.
  71. Goldstein I, Lines C, Pyke R, Scheld JS. National differences in patient-clinician communication regarding hypoactive sexual desire disorder. J Sex Med. 2009;6(5):1349-1357.
  72. Grewal GS, Gill JS, Sidi H, Gurpreet K, Jambunathan ST, Suffee NJ, Midin M, Jaafar NR, Das S.Prevalence and risk factors of female sexual dysfunction among healthcare personnel in malaysia. Compr Psychiatry. 2013 Feb 26. [Epub ahead of print]
  73. Guay AT, Director, Center for Sexual Function, Lahey Clinic Northshore, Peabody, MA, and Clinical Assistant Professor of Medicine (Endocrinology), Harvard Medical School, Boston, MA, written responses to in-depth physician interview, July 23, 2009.
  74. Harsh V, McGarvey EL, Clayton AH. Physician attitudes regarding hypoactive sexual desire disorder in a primary care clinic: a pilot study. J Sex Med. 2008;5(3):640-645.
  75. Hassanin IM, Helmy YA, Fathalla MM, Shahin AY. Prevalence and characteristics of female sexual dysfunction in a sample of women from Upper Egypt. Int J Gynaecol Obstet. 2010;108(3):219-223.
  76. Hawkes N. Do drugs have a role in turning indifference into passion? BMJ. 2010 5;341:c5532.
  77. Hayes RD, Dennerstein L, Bennett CM, Koochaki PE, Leiblum SR, Graziottin A.Relationship between hypoactive sexual desire disorder and aging. Fertil Steril. 2007;87(1):107-112.
  78. Heiman JR, Rupp H, Janssen E, Newhouse SK, Brauer M, Laan E. Sexual desire, sexual arousal and hormonal differences in premenopausal US and Dutch women with  and without low sexual desire. Horm Behav. 2011;59(5):772-779.
  79. Hernández Hernández JR, López-Tomassetti Fernández E, Caballero Díaz Y, Molina Cabrillana J, Morales García D, Núñez Jorge V.Remission of the female sexual dysfunction in morbidly obese female patients with the Scopinaro procedure.Surg Obes Relat Dis. 2013 Feb 28. [Epub ahead of print]
  80. Holloway V, Wylie K. Sex drive and sexual desire. Curr Opin Psychiatry. 2015;28(6):424-9.
  81. Hucker A, McCabe MP. Manualized Treatment Programs for FSD: Research Challenges and Recommendations. J Sex Med. 2011 Dec 21. [Epub ahead of print].
  82. Ibrahim ZM, Ahmed MR, Ahmed WA.Prevalence and risk factors for female sexual dysfunction among Egyptian women.Arch Gynecol Obstet. 2013;287(6):1173-80.
  83. Ishak IH, Low WY, Othman S. Prevalence, risk factors, and predictors of female sexual dysfunction in a primary care setting: a survey finding. J Sex Med. 2010;7(9):3080-3087.
  84. Isidori AM, Pozza C, Esposito K, Giugliano D, Morano S, Vignozzi L, Corona G, Lenzi A, Jannini EA. Development and validation of a 6-item version of the female sexual function index (FSFI) as a diagnostic tool for female sexual dysfunction. J Sex Med. 2010 Mar;7(3):1139-1146.
  85. Jacob KA, Bell J, Francis S. Resident training in female sexual dysfunction: a comparison of urology and obstetrics and gynecology programs.Female Pelvic Med Reconstr Surg. 2011;17(5):238-241.
  86. Jayne C, Simon JA, Taylor LV, Kimura T, Lesko LM, on behalf of the SUNFLOWER study investigators. Open-label extension study of flibanserin in women with hypoactive sexual desire disorder. J Sex Med. 2012;9(12):3180-3188.
  87. Jin J. JAMA PATIENT PAGE. Flibanserin for Treating Low Sexual Desire in Women. JAMA. 2015 Sep 22-29;314(12):1312. doi: 10.1001/jama.2015.11769.
  88. Kadioglu P, Yetkin DO, Sanli O, Yalin AS, Onem K, Kadioglu A. Obesity might not be a risk factor for female sexual dysfunction. BJU Int. 2010 Nov;106(9):1357-1361.
  89. Katz M, Derogatis LR, Ackerman R, Hedges P, Lesko L, Garcia M Jr, Sand M; BEGONIA trial investigators. Efficacy of Flibanserin in Women with Hypoactive Sexual Desire Disorder: Results from the BEGONIA Trial. J Sex Med. 2013;10(7):1807-1815.
  90. Kennedy S. Flibanserin: initial evidence of efficacy on sexual dysfunction, in patients with major depressive disorder. J Sex Med. 2010;7(10):3449-3459.
  91. Kim YH, Kim SM, Kim JJ, Cho IS, Jeon MJ. Does metabolic syndrome impair sexual function in middle- to old-aged women? J Sex Med. 2011;8(4):1123-1130.
  92. Kingsberg SA, Rezaee RL. Hypoactive sexual desire in women. Menopause. 2013;20(12):1284-300.
  93. Kingsberg S. Testosterone treatment for hypoactive sexual desire disorder in postmenopausal women. J Sex Med. 2007;4(suppl 3):227-234.
  94. Kingsberg SA, Althof SE. Satisfying sexual events as outcome measures in clinical trial of female sexual dysfunction. J Sex Med. 2011;8(12):3262-3270.
  95. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281(6):537-544.
  96. Leiblum SR, Koochaki PE, Rodenberg CA, Barton IP, Rosen RC. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS). Menopause. 2006;13(1):46-56.
  97. Lenzer J. Boehringer Ingelheim withdraws libido drug for women. BMJ. 2010 Oct 12;341:c5701.
  98. Levine SB. Flibanserin. Arch Sex Behav. 2015 Sep 16. [Epub ahead of print]
  99. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med. 2007;357(8):762-774.
  100. Lodise NM.Hypoactive sexual desire disorder in women: treatment options beyond testosterone and approaches to communicating with patients on sexual health. Pharmacotherapy. 2013;33(4):411-421.
  101. Margo K, Winn R. Testosterone treatments: why, when, and how? Am Fam Physician. 2006;73(9):1591-1598.
  102. Martelli V, Valisella S, Moscatiello S, Matteucci C, Lantadilla C, Costantino A, Pelusi G, Marchesini G, Meriggiola MC. Prevalence of Sexual Dysfunction among Postmenopausal Women with and without Metabolic Syndrome. J Sex Med. 2012;9(2):434-441.
  103. Martelli V, Valisella S, Moscatiello S, Matteucci C, Lantadilla C, Costantino A,  Pelusi G, Marchesini G, Meriggiola MC. Prevalence of sexual dysfunction among postmenopausal women with and without metabolic syndrome. J Sex Med. 2012;9(2):434-441
  104. Martinez L, Executive Director, Women’s Sexual Health Foundation, personal communication, November 13, 2008. Nusbaum MRH, Hamilton CD. The proactive sexual health history. Am Fam Physician. 2002;66(9):1705-1712.
  105. Maserejian NN, Parish S, Shifren JL, Huang L, Gerstenberger E, Rosen RC. Healthcare utilization in women diagnosed with hypoactive sexual desire disorder: interim baseline results from the HSDD Registry for Women. J Womens Health (Larchmt). 2010;19(11):2001-2009.
  106. Maserejian NN, Shifren J, Parish SJ, Segraves RT, Huang L, Rosen RC. Sexual arousal and lubrication problems in women with clinically diagnosed hypoactive sexual desire disorder: preliminary findings from the hypoactive sexual desire disorder registry for women. J Sex Marital Ther. 2012;38(1):41-62.
  107. Maserejian NN, Shifren JL, Parish SJ, Braunstein GD, Gerstenberger EP, Rosen RC. The presentation of hypoactive sexual desire disorder in premenopausal women. J Sex Med. 2010;7(10):3439-3448.
  108. McCabe MP, Jones LM. Attrition from an Internet-based treatment program for female sexual dysfunction: Who is best treated with this approach?Psychol Health Med. 2013 Jan 31. [Epub ahead of print]
  109. Miner M, Esposito K, Guay A, Montorsi P, Goldstein I. Cardiometabolic risk and female sexual health: the Princeton III summary. J Sex Med. 2012;9(3):641-652.
  110. Miner M, Sadovsky R, Buster JE.Hypoactive sexual desire disorder in premenopausal women: case studies.Postgrad Med. 2012;124(1):94-103.
  111. Moore RH, Sarwer DB, Lavenberg JA, Lane IB, Evans JL, Volger S, Wadden TA. Relationship between sexual function and quality of life in obese persons seeking weight reduction.Obesity (Silver Spring). 2013 Mar 20.[Epub ahead of print]
  112. Nachtigall L, Casson P, Lucas J, Schofield V, Melson C, Simon JA. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol Endocrinol. 2011;27(1):39-48
  113. Nappi RE, Albani F, Santamaria V, Tonani S, Martini E, Terreno E, Brambilla E, Polatti F. Menopause and sexual desire: the role of testosterone. Menopause Int. 2010;16(4):162-168. Review.
  114. Nappi RE, Martini E, Terreno E, Albani F, Santamaria V, Tonani S, Chiovato L, Polatti F. Management of hypoactive sexual desire disorder in women: current and emerging therapies. Int J Womens Health. 2010;2:167-175.
  115. Nappi RE, Martini E, Terreno E, Albani F, Santamaria V, Tonani S, Chiovato L, Polatti F. Management of hypoactive sexual desire disorder in women: current and emerging therapies. Int J Womens Health. 2010;2:167-175.
  116. Nappi RE. Why are there no FDA-approved treatments for female sexual dysfunction? Expert Opin Pharmacother. 2015;16(12):1735-8.
  117. Nowosielski K, Drosdzol A, Sipiñski A, Kowalczyk R, Skrzypulec V. Diabetes mellitus and sexuality--does it really matter? J Sex Med. 2010;7(2 Pt 1):723-735.
  118. Nowosielski K, Wróbel B, Sioma-Markowska U, Poreba™ba R. Development and validation of the Polish version of the Female Sexual Function Index in the Polish population of females. J Sex Med. 2013;10(2):386-395.
  119. Nowosielski K, Wróbel B, Sioma-Markowska U, Poreba™ R.Sexual dysfunction and distress--development of a Polish version of the female sexual distress scale-revised. J Sex Med. 2013;10(5):1304-1312.
  120. Osborne V, Hazell L, Layton D, Shakir SA. Drug utilization of Intrinsa (testosterone patch) in England: interim analysis of a prescription-event monitoring study to support risk management. Drug Saf. 2010;33(3):213-221.
  121. Pakpour AH, Yekaninejad MS, Zeidi IM, Burri A. Prevalence and risk factors of the female sexual dysfunction in a sample of infertile Iranian women. Arch Gynecol Obstet. 2012;286(6):1589-1596.
  122. Palacios S. Hypoactive Sexual Desire Disorder and current pharmacotherapeutic options in women. Womens Health (Lond Engl). 2011;7(1):95-107. Review.
  123. Panay N, Al-Azzawi F, Bouchard C, Davis SR, Eden J, Lodhi I, Rees M, Rodenberg CA, Rymer J, Schwenkhagen A, Sturdee DW. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric. 2010;13(2):121-131.
  124. Parish S, Associate Professor of Medicine, Department of Medicine, Albert Einstein College of Medicine, and Montefiore Medical Center, Bronx, NY, oral responses to in-depth physician interview, July 21, 2009.
  125. Pasquali D, Maiorino MI, Renzullo A, Bellastella G, Accardo G, Esposito D, Barbato F, Esposito K. Female sexual dysfunction in women with thyroid disorders. J Endocrinol Invest. 2013 Apr 12. [Epub ahead of print]
  126. Pauls RN, Kleeman SD, et al. Int Urogynecol J Pelvic Floor Dysfunct. 2005;16(6):460-467.
  127. Poels S, Bloemers J, van Rooij K, Koppeschaar H, Olivier B, Tuiten A. Two novel combined drug treatments for women with hypoactive sexual desire disorder. Pharmacol Biochem Behav. 2014;121:71-79.
  128. Pontiroli AE, Cortelazzi D, Morabito A. Female sexual dysfunction and diabetes: a systematic review and meta-analysis. J Sex Med. 2013;10(4):1044-1051.
  129. Revicki DA, Margolis MK, Bush EN, DeRogatis LR, Hanes V. Content validity of the Female Sexual Function Index (FSFI) in pre- and postmenopausal women with hypoactive sexual desire disorder. J Sex Med. 2011;8(8):2237-2245.
  130. Reviriego C. Flibanserin for female sexual dysfunction. Drugs Today (Barc). 2014;50(8):549-56.
  131. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'Agostino R. The female sexual function index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208.
  132. Rosen RC, Connor MK, Miyasato G, Link C, Shifren JL, Fisher WA, Derogatis LR, Schobelock MJ. Sexual Desire Problems in Women Seeking Healthcare: A Novel Study Design for Ascertaining Prevalence of Hypoactive Sexual Desire Disorder in Clinic-Based Samples of U.S. Women. J Womens Health (Larchmt). 2012 Jan 9. [Epub ahead of print].
  133. Rosen RC, Maserejian NN, Connor MK, Krychman ML, Brown CS, Goldstein I. Characteristics of premenopausal and postmenopausal women with acquired, generalized hypoactive sexual desire disorder: the Hypoactive Sexual Desire Disorder Registry for women. Menopause. 2011 Nov 10. [Epub ahead of print].
  134. Rosen RC, Shifren JL, Monz BU, Odom DM, Russo PA, Johannes CB. Correlates of sexually related personal distress in women with low sexual desire. J Sex Med. 2009;6(6):1549-1560.
  135. Ryding EL, Blom C. Validation of the Swedish version of the Female SexuaL Function Index (FSFI) in women with hypoactive sexual desire disorder. J Sex Med. 2015;12(2):341-9.
  136. Sadovsky R, Alam W, Enecilla M, Cosiquien R, Tipu O, Etheridge-Otey J. Sexual problems among a specific population of minority women aged 40-80 years attending a primary care practice. J Sex Med. 2006;3(5):795-803.
  137. Safarinejad MR, Hosseini SY, Asgari MA, Dadkhah F, Taghva A. A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women. BJU Int. 2010;106(6):832-839.
  138. Shaeer O, Shaeer K, Shaeer E. The Global Online Sexuality Survey (GOSS): Female Sexual Dysfunction among Internet Users in the Reproductive Age Group in the Middle East. J Sex Med. 2012 ;9(2):411-24.
  139. Shahar MA, Hussein H, Sidi H, Shah SA, Mohamed Said MS. Sexual dysfunction and its determinants in Malaysian women with rheumatoid arthritis. Int J Rheum Dis. 2012;15(5):468-77.
  140. Shi YF, Shao XY, Lou QQ, Chen YJ, Zhou HJ, Zou JY. Study on female sexual dysfunction in type 2 diabetic Chinese women. Biomed Environ Sci. 2012;25(5):557-561.
  141. Shifren JL, Johannes CB, Monz BU, Russo PA, Bennett L, Rosen R. Help-seeking behavior of women with self-reported distressing sexual problems. J Womens Health (Larchmt). 2009;18(4):461-468.
  142. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112(5):970-978.
  143. Simon JA, Kingsberg SA, Shumel B, Hanes V, Garcia M Jr, Sand M. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desiredisorder: results of the SNOWDROP trial. Menopause. 2014;21(6):633-640.
  144. Simon JA. Low sexual desire--is it all in her head? Pathophysiology, diagnosis, and treatment of hypoactive sexual desire disorder. Postgrad Med. 2010;122(6):128-136. Review.
  145. Snabes MC, Simes SM. Approved hormonal treatments for HSDD: an unmet medical need. J Sex Med. 2009;6(7):1846-1849.
  146. Stahl SM. Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder. CNS Spectr. 2015;20(1):1-6.
  147. Stahl SM, Sommer B, Allers KA. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med. 2011;8(1):15-27. Review.
  148. Stahl SM. Targeting circuits of sexual desire as a treatment strategy for hypoactive sexual desire disorder. J Clin Psychiatry. 2010;71(7):821-822. Review.
  149. Strecker K, Adamaszek M, Ohm S, Wegner F, Beck J, Schwarz J. The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice. J Neural Transm. 2012;119(11):1351-9.
  150. Symonds T, Abraham L, Bushmakin AG, Williams K, Martin M, Cappelleri JC.Sexual function questionnaire: further refinement and validation.J Sex Med. 2012;9(10):2609-2616.
  151. Thorp J Jr, Palacios S, Symons J, Simon J, Barbour K. Improving prospects for treating hypoactive sexual desire disorder (HSDD): development status of flibanserin. BJOG. 2014;121(11):1328-1331.
  152. Thorp J, Simon J, Dattani D, Taylor L, Kimura T, Garcia M Jr, Lesko L, Pyke R; DAISY trial investigators. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med. 2012;9(3):793-804.
  153. Trocóniz IF, Boland K, Staab A. Population Pharmacokinetic/Pharmacodynamic Model for the Sedative Effects of Flibanserin in Healthy Volunteers. Pharm Res. 2012;29(6):1518-29.
  154. van Rooij K, Poels S, Bloemers J, Goldstein I, Gerritsen J, van Ham D, van Mameren F, Chivers M, Everaerd W, Koppeschaar H, Olivier B, Tuiten A.Toward personalized sexual medicine (part 3): testosterone combined with a Serotonin1A receptor agonist increases sexual satisfaction in women with HSDD and FSAD, and dysfunctional activation of sexual inhibitory mechanisms.J Sex Med. 2013;10(3):824-837.
  155. Varghese KM, Bansal R, Kekre AN, Jacob KS.Sexual dysfunction among young married women in southern India.Int Urogynecol J. 2012;23(12):1771-1774.
  156. Veronelli A, Mauri C, Zecchini B, et al. Sexual dysfunction is frequent in premenopausal women with diabetes, obesity, and hypothyroidism, and correlates with markers of increased cardiovascular risk: a preliminary report. J Sex Med. 2009;6(6):1561-1568.
  157. Wallwiener CW, Wallwiener LM, Seeger H, Mück AO, Bitzer J, Wallwiener M. Prevalence of sexual dysfunction and impact of contraception in female German medical students. J Sex Med. 2010;7(6):2139-2148.
  158. West SL, D'Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch Intern Med. 2008;168(13):1441-1449.  
  159. White WB, Grady D, Giudice LC, Berry SM, Zborowski J, Snabes MC. A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder. Am Heart J. 2012;163(1):27-32.
  160. Wing RR, Bond DS, Gendrano IN 3rd, Wadden T, Bahnson J, Lewis CE, Brancati F, Schneider S, Kitabchi AE, Van Dorsten B, Rosen RC; Effect of Intensive Lifestyle Intervention on Sexual Dysfunction in Women With Type 2 Diabetes: Results from an ancillary Look AHEAD study.The Sexual Dysfunction Subgroup of the Look AHEAD Research Group. Diabetes Care. 2013 Jun 11. [Epub ahead of print].
  161. Woodard TL, Nowak NT, Balon R, Tancer M, Diamond MP. Brain activation patterns in women with acquired hypoactive sexual desire disorder and women with normal sexual function: a cross-sectional pilot study. Fertil Steril. 2013 Jul 2. [Epub ahead of print].
  162. Woodis CB, McLendon AN, Muzyk AJ.Testosterone supplementation for hypoactive sexual desire disorder in women. Pharmacotherapy. 2012;32(1):38-53.
  163. Wyllie MG. Resurgence of interest in sexual dysfunction? BJU Int. 2012;109(11):E36-7.
  164. Yaylali GF, Tekekoglu S, Akin F. Sexual dysfunction in obese and overweight women. Int J Impot Res. 2010;22(4):220-226.
  165. Zhang H, Yip PS. Female sexual dysfunction among young and middle-aged women in Hong Kong: prevalence and risk factors. J Sex Med. 2012;9(11):2911-2918.